Drugs / Prostap® 3 DCS
last change Feb 2014 re-read 2 minutes ago

Prostap® 3 DCS

Developed for
prostate cancer

Trials 0

Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 4 NCT01673984 Comparator Aug 2012 → Feb 2014 prostate cancer Ipsen Terminated No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Prostap 3 DCS ClinicalTrials.gov intervention name — accepted as the source's own label NCT01673984
Route Subcutaneous “11.25mg, depot injected subcutaneously” NCT01673984